Abstract Title:
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Summary:
The DREAMM-8 study compared the effectiveness and safety of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) to pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). The study showed that BPd significantly improved progression-free survival (PFS) compared to PVd, with a higher 12-month PFS rate. BPd also resulted in a higher overall response rate and a greater rate of complete response or better. The duration of response was longer with BPd. Adverse events were reported in both groups, but ocular adverse events were more common with BPd. The safety profile of both treatments was manageable. These findings suggest that BPd is a promising treatment option for RRMM patients.
Key Points:
- The DREAMM-8 study demonstrated a significant and clinically meaningful improvement in progression-free survival (PFS) with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) compared to pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM).
- The 12-month PFS rate was higher in the BPd arm (71% vs 51%).
- The overall response rate (ORR) was 77% in the BPd arm and 72% in the PVd arm, with a higher rate of complete response or better in the BPd arm (40% vs 16%).
- The median duration of response was not reached in the BPd arm and was 17.5 months in the PVd arm.
- Adverse events (AEs) were reported in over 99% of patients in the BPd arm and 96% in the PVd arm, with ocular AEs being more common in the BPd arm (grade 3/4 in 43% vs 2% in the PVd arm).
- The safety profile of both regimens was manageable and consistent with the known safety profile of the individual agents.
Authors:
Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir I. Vorobyev, Michele Cavo, Kazuhito Suzuki, Pawel Robak, Kristin Morris, Amy Phillips-Jones, Xiaoou Linnette Zhou, Giulia Fulci, Neal Sule, Brandon Kremer, Joanna Opalinska, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos
Clinical Trial Registration Number: NCT04484623
ASCO Abstract# LBA105
DOI: 10.1200/JCO.2024.42.17_suppl.LBA105
